Clinical trials: Diffuse Systemic Sclerosis
Scleroderma
High Dose Cyclophosphamide for Treatment of Scleroderma
Systemic Sclerosis (Scleroderma) varies greatly in clinical manifestations, mode of presentation, and course. The natural history of this chronic autoimmune disease ranges from benign to fatal.
- Trial name
- NCT00501995
- Testing
- IV Cyclophosphamide
- Volunteers
- 6 people
- Sponsor
- Johns Hopkins University
Carpal Tunnel Syndrome, Chronic Pain
Local Injection of Ozone Versus Methylprednisolone Acetate in Carpal Tunnel Syndrome of Scleroderma Patients
Carpal tunnel syndrome is a common peripheral entrapment neuropathy, this study aims to investigate if, and to what extent local ozone therapy could offer symptom improvement in scleroderma patients with Carpal tunnel syndrome
- Conditions
- Carpal Tunnel Syndrome, Chronic Pain, Scleroderma
- Trial name
- NCT03742466
- Testing
- Ozone, methylprednisolone acetate
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Limited Scleroderma, Diffuse Scleroderma
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.
- Trial name
- NCT01881529
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Gilead Sciences
Scleroderma, Systemic Sclerosis
Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients
Scleroderma, or systemic sclerosis (SSc), is a diffuse connective tissue disease characterized by changes in the skin, blood vessels, skeletal muscles, and internal organs.
- Trial name
- NCT00040651
- Testing
- Fludarabine, Cyclophosphamide, Thymoglobulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Systemic Sclerosis, Scleroderma
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse cutaneous systemic scleroderma (dcSSc).
- Trial name
- TOFA-SSc (NCT03274076)
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Scleroderma
Genesis of Scleroderma: Role of Environmental Factors in 100 Patients With Scleroderma and 300 Controls
Scleroderma is an autoimmune disease of unknown origin. Recently, the role of environmental factors, and particularly toxic drug exposure, in the genesis of scleroderma has been suggested.
- Trial name
- NCT00213525
- Testing
- Questionnary for environmental factors research
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University Hospital, Rouen
Raynaud's Disease
Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile secondary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048776
- Testing
- Pletal
- Where
- 19 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Autoimmune Diseases, Sickle Cell Disease
Microvascular and Fibrosis Imaging Study
In this study, Laser Doppler Flowmetry (LDF), Laser Doppler Imaging (LDI), Orthogonal Polarization Spectral Imaging (OPSI), Nail fold video capillaroscopy (NVC) and Optical Coherence Tomography (OCT) will be used to assess…
- Conditions
- Autoimmune Diseases, Sickle Cell Disease, Chronic Graft Versus Host Disease
- Trial name
- NCT01758250
- Testing
- Acoustic Radiation Force Impulse (ARFI), Laser Doppler Flowmetry (LDF), Laser Doppler Perfusion Imaging (LDI)
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Duke University
Raynaud Disease
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
In this double-blinded, placebo-controlled, fixed-dose, study patients will be randomly assigned to take placebo or 20 mg tadalafil thrice weekly for 6 weeks.
- Trial name
- NCT00626665
- Testing
- Tadalafil
- Volunteers
- 25 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Scleroderma
Premature Coronary Atherosclerosis in Scleroderma
The purpose of this trial is to study the proportion of scleroderma patients who suffer from asymptomatic coronary atherosclerosis compared to healthy controls.
- Trial name
- NCT00372398
- Where
- Hong Kong
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Tuen Mun Hospital
Interstitial Lung Disease, Scleroderma
Effects of Whole Body Vibration Training in Patients With Interstitial Lung Disease
Interstitial lung disease (ILD) is a diverse group of parenchymal lung disorders characterized by restrictive lung function and impaired alveolar diffusion capacity, leading to dyspnea on exertion, reduced exercise endurance, and…
- Conditions
- Interstitial Lung Disease, Scleroderma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT03560154
- Testing
- Whole Body Vibration Training
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Istanbul University
Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
- Conditions
- Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
- Trial name
- NCT06400303
- Testing
- KYV-101, Standard lymphodepletion regimen
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Kyverna Therapeutics
Systemic Sclerosis
Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma.
Diffuse infiltrating pneumonia (DIP) is a severe complication of systemic sclerosis and one of the leading cause of death in this condition.
- Trial name
- SCLERO-PID (NCT03271333)
- Testing
- lung function tests
- Where
- 2 sites in France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Lille
Systemic Sclerosis, Scleroderma
Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is an autoimmune disease with unknown etiology, which affects especially the gastrointestinal tract, lungs, heart and kidneys.
- Trial name
- SSc (NCT02302352)
- Testing
- Probiotic
- Where
- Brazil
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Scleroderma
RENEW Scleroderma: A Peer-Mentored, Web Intervention for Resilience-based, Energy Management to Enhance Wellbeing and Fatigue
The researchers seek to understand if the Resilience-based, Energy Management to Enhance Wellbeing and Fatigue (RENEW) program helps with scleroderma symptom management and disease burden.
- Trial name
- RENEW (NCT04908943)
- Testing
- RENEW
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- University of Michigan
Diffuse Systemic Sclerosis
Serial Night Time Position Splint on Systemic Sclerosis
This is a randomized controlled trial with blinded evaluator and follow-up of one year. Seventy six patients with diffuse systemic sclerosis, will be randomized into two groups.The patients can not change their medication during…
- Trial name
- NCT01586663
- Testing
- Serial night time position splint, Drug treatment
- Where
- Brazil
- Volunteers
- 76 people
- Sponsor
- Federal University of São Paulo
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Scleroderma
MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients
Assessment of pulmonary fibrosis is currently based on high-resolution CT (HRCT) and pulmonary function tests (PFT) such as forced vital capacity, (FVC) and carbon monoxide diffusion (DLCO).
- Trial name
- IRMSCLERO (NCT03207997)
- Testing
- unenhanced MR sequences
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Morphea, Scleroderma, Localized
A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)
A two-component therapeutic consisting of FCX-013 and veledimex for the treatment of localized scleroderma (or morphea). The first component, FCX-013, is autologous human fibroblasts genetically-modified using lentivirus and…
- Conditions
- Morphea, Scleroderma, Localized, Scleroderma
- Trial name
- NCT03740724
- Testing
- FCX-013, veledimex
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Castle Creek Biosciences, LLC.
RA, SLE
Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response
The overall objective of this project is to study the influence of modern anti-inflammatory treatments in established inflammatory rheumatic diseases (IRD) on immune response elicited by pneumococcal vaccination using 13-valent…
- Conditions
- RA, SLE, Vasculitis, Scleroderma
- Trial name
- Vaccimil (NCT02240888)
- Testing
- 0,5 mg Prevenar i.m., 0,5 mg seasonal influenza vaccine i.m.
- Where
- Sweden
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Region Skane